These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30547188)

  • 1. Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.
    Lamm W; Kiesewetter B; Puhr H; Dolak W; Mayerhöfer ME; Raderer M
    Ann Hematol; 2019 Jun; 98(6):1519-1520. PubMed ID: 30547188
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

  • 4. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
    Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
    Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
    Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 7. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare composite lymphoma: follicular and in situ mantle cell.
    Marí-Jimenez P; Martínez-Losada C; Centeno-Haro M; Rodríguez-García G; Perez-Seoane C; Sánchez-García J
    Ann Hematol; 2016 Aug; 95(8):1351-2. PubMed ID: 27103006
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
    Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
    Kambhampati S; Fakhri B; Ai WZ; Kaplan LD; Tuscano JM; Wieduwilt MJ; Sudhindra A; Cavallone E; Reiner J; Aoun C; Castillo M; Martinelli M; Ta T; Le D; Padilla M; Crawford E; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):139-146. PubMed ID: 33478921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
    Gressin R; Daguindau N; Tempescul A; Moreau A; Carras S; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Pignon JM; Corm S; Banos A; Mounier C; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouadallah K; Amorin S; Garidi R; Voillat L; Joly B; Celigny PS; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Le Gouill S; Callanan MB;
    Haematologica; 2019 Jan; 104(1):138-146. PubMed ID: 30171024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
    Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA
    Leuk Lymphoma; 2017 Jul; 58(7):1589-1597. PubMed ID: 27838951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
    Sivaraj D; Green MM; Kang Y; Long GD; Rizzieri DA; Li Z; Garrett AH; McIntyre JL; Chao NJ; Gasparetto C
    Blood Cancer J; 2018 Jul; 8(8):71. PubMed ID: 30065277
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
    Scapinello G; Riva M; Branca A; Pizzi M; Bonaldi L; Martines A; Manni S; Visentin A; Trentin L; Semenzato G; Gurrieri C; Piazza F
    Ann Hematol; 2020 Nov; 99(11):2715-2717. PubMed ID: 32671454
    [No Abstract]   [Full Text] [Related]  

  • 17. Bendamustine and G-CSF support.
    Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N
    Support Care Cancer; 2019 May; 27(5):1581-1582. PubMed ID: 29484498
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.
    Kamdar M; Li H; Chen RW; Rimsza LM; Leblanc ML; Fenske TS; Shea TC; Barr PM; Phillips TJ; Leonard JP; Kahl BS; Friedberg JW; Smith SM
    Blood Adv; 2019 Oct; 3(20):3132-3135. PubMed ID: 31648328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.